Compare · LSTA vs SHC
LSTA vs SHC
Side-by-side comparison of Lisata Therapeutics Inc. (LSTA) and Sotera Health Company (SHC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LSTA and SHC operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- SHC is the larger of the two at $5.16B, about 446.1x LSTA ($11.6M).
- LSTA has been more active in the news (9 items in the past 4 weeks vs 2 for SHC).
- SHC has more recent analyst coverage (25 ratings vs 0 for LSTA).
- Company
- Lisata Therapeutics Inc.
- Sotera Health Company
- Price
- -
- -
- Market cap
- $11.6M
- $5.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 9
- 2
- Recent ratings
- 0
- 25
Sotera Health Company
Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
Latest LSTA
- SEC Form 3 filed by Lisata Therapeutics Inc.
- SEC Form 8-K filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
- SEC Form PRE 14A filed by Lisata Therapeutics Inc.
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
- SEC Form D filed by Lisata Therapeutics Inc.
- New insider Love Ted W claimed ownership of 19,260 shares (SEC Form 3)
- New insider Lehrer-Graiwer Joshua claimed ownership of 27,808 shares (SEC Form 3)
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Latest SHC
- Sotera Health downgraded by Analyst with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company
- Executive Chairman Petras Michael B. Jr. sold $21,174,786 worth of shares (1,144,515 units at $18.50), decreasing direct ownership by 43% to 397,912 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company
- Sotera Health Company filed SEC Form 8-K: Leadership Update
- President of Sterigenics Rutz Michael P sold $2,825,250 worth of shares (150,000 units at $18.84), decreasing direct ownership by 31% to 334,279 units (SEC Form 4)
- Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 11,316 shares, decreasing direct ownership by 5% to 217,304 units (SEC Form 4) (tax liability)
- SEC Form 144 filed by Sotera Health Company
- SEC Form 10-Q filed by Sotera Health Company
- Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits